Format
Items per page
Sort by

Send to:

Choose Destination

Results: 16

1.

No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with schizophrenia.

Li J, Li X, Liu E, Copeland P, Freudenreich O, Goff DC, Henderson DC, Song X, Fan X.

Schizophr Res. 2013 May;146(1-3):40-5. doi: 10.1016/j.schres.2013.01.034. Epub 2013 Feb 21.

2.

Fighting the good fight: responsibility and rationale in the confrontation of patients.

Kontos N, Querques J, Freudenreich O.

Mayo Clin Proc. 2012 Jan;87(1):63-6. doi: 10.1016/j.mayocp.2011.07.002. No abstract available.

3.

Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia.

Borba CP, Fan X, Copeland PM, Paiva A, Freudenreich O, Henderson DC.

J Clin Psychopharmacol. 2011 Oct;31(5):653-8. doi: 10.1097/JCP.0b013e31822bb573.

4.

Depressogenic effects of medications: a review.

Celano CM, Freudenreich O, Fernandez-Robles C, Stern TA, Caro MA, Huffman JC.

Dialogues Clin Neurosci. 2011;13(1):109-25. Review.

5.

A case of dramatic improvement of severe tardive dyskinesia after switch to aripiprazole.

Brown HE, Flaherty AW, Goff DC, Freudenreich O.

Prim Care Companion CNS Disord. 2011;13(6). pii: PCC.11l01188. doi: 10.4088/PCC.11l01188. No abstract available.

6.

Management of psychosis associated with a prolactinoma: case report and review of the literature.

Ali S, Miller KK, Freudenreich O.

Psychosomatics. 2010 Sep-Oct;51(5):370-6. doi: 10.1176/appi.psy.51.5.370. Review.

7.

The assessment and management of agitation and delirium in the general hospital.

Stern TA, Celano CM, Gross AF, Huffman JC, Freudenreich O, Kontos N, Nejad SH, Repper-Delisi J, Thompson BT.

Prim Care Companion J Clin Psychiatry. 2010;12(1):PCC.09r00938. doi: 10.4088/PCC.09r00938yel. No abstract available.

8.

Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR).

Freudenreich O, Brockman MA, Henderson DC, Evins AE, Fan X, Walsh JP, Goff DC.

Psychiatry Res. 2010 Apr 30;176(2-3):99-102. doi: 10.1016/j.psychres.2008.11.007. Epub 2010 Feb 4.

9.

Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine.

Henderson DC, Fan X, Sharma B, Copeland PM, Borba CP, Freudenreich O, Cather C, Evins AE, Goff DC.

J Psychiatr Pract. 2009 Jul;15(4):251-61. doi: 10.1097/01.pra.0000358312.99233.ef.

10.

Dysfunction of a cortical midline network during emotional appraisals in schizophrenia.

Holt DJ, Lakshmanan B, Freudenreich O, Goff DC, Rauch SL, Kuperberg GR.

Schizophr Bull. 2011 Jan;37(1):164-76. doi: 10.1093/schbul/sbp067. Epub 2009 Jul 15.

11.

Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.

Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC.

J Clin Psychopharmacol. 2009 Apr;29(2):165-9. doi: 10.1097/JCP.0b013e31819a8dbe.

12.

Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia.

Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Forstbauer SI, Miley K, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC.

Hum Psychopharmacol. 2009 Apr;24(3):225-32. doi: 10.1002/hup.1012.

13.

Predictors of early abstinence in smokers with schizophrenia.

Culhane MA, Schoenfeld DA, Barr RS, Cather C, Deckersbach T, Freudenreich O, Goff DC, Rigotti NA, Evins AE.

J Clin Psychiatry. 2008 Nov;69(11):1743-50. Epub 2008 Oct 21.

14.

A placebo-controlled study of sildenafil effects on cognition in schizophrenia.

Goff DC, Cather C, Freudenreich O, Henderson DC, Evins AE, Culhane MA, Walsh JP.

Psychopharmacology (Berl). 2009 Jan;202(1-3):411-7. doi: 10.1007/s00213-008-1278-5. Epub 2008 Aug 21.

15.

High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia.

Dyer MA, Freudenreich O, Culhane MA, Pachas GN, Deckersbach T, Murphy E, Goff DC, Evins AE.

Schizophr Res. 2008 Jul;102(1-3):88-95. doi: 10.1016/j.schres.2007.12.491. Epub 2008 Mar 5.

16.

A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.

Goff DC, Lamberti JS, Leon AC, Green MF, Miller AL, Patel J, Manschreck T, Freudenreich O, Johnson SA.

Neuropsychopharmacology. 2008 Feb;33(3):465-72. Epub 2007 May 9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk